Momelotinib Dihydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Momelotinib Dihydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
28
Registered trials
67
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Momelotinib Dihydrochloride can convert its Small molecule drug profile and ALK2 x JAK1 x JAK2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Momelotinib Dihydrochloride (query alias: Momelotinib Dihydrochloride) |
|---|---|
| Modality / target | Small molecule drug; ALK2 x JAK1 x JAK2; ALK2 inhibitors, JAK1 inhibitors, JAK2 inhibitors |
| Highest global status | Approved |
| Originator | Gilead Sciences, Inc. |
| Active developers | GSK Plc, GlaxoSmithKline Trading Services Ltd., GlaxoSmithKline Australia Pty Ltd. |
The MCP disease footprint includes Post-essential thrombocythemia myelofibrosis, Post-polycythemia vera myelofibrosis, Primary Myelofibrosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07498205 | Phase 4 | Not yet recruiting | 268 | To estimate and compare the proportion of participants achieving a dual response [SVR35] and transfusion independence response from red blood cell transfusions. |
| NCT07569081 | Phase 2/3 | Not yet recruiting | 136 | ORR (Objective response rate) at Week 26 |
| ISRCTN98283910 | Phase 2 | Not yet recruiting | 40 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
INVESTIGATIONAL PIM1 INHIBITOR NUVISERTIB IN COMBINATION WITH MOMELOTINIB SHOWED PROMISING CLINICAL ACTIVITY IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA: DATA FROM AN ONGOING GLOBAL PHASE 1/2 STUDY
Phase 1/2; n=26; evaluation: Positive. Reported fields: SVR25(Wk12) = 73.0 %
CLINICAL OUTCOMES OF MOMELOTINIB IN A REAL-WORLD COHORT OF PATIENTS WITH MYELOFIBROSIS
Not Applicable; n=10; evaluation: Positive. Reported fields: Hgb response(≥1 g/dL increase) = 7.0 Pts
REAL-WORLD APPLICATION OF 2024 IWG-ELN CRITERIA FOR ANEMIA RESPONSE IN MOMELOTINIB-TREATED MYELOFIBROSIS
Not Applicable; n=29; evaluation: Positive. Reported fields: ORR(3-month) = 60.0 % ; ORR(3-month) = 56.0 % ; ORR(3-month) = 55.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Momelotinib Dihydrochloride addresses Post-essential thrombocythemia myelofibrosis, Post-polycythemia vera myelofibrosis, Primary Myelofibrosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-04-13 | Sareum notes proposed acquisition of Sierra Oncology by GSK. | Phase 2 | US$1,900.0M stated total |
| 2021-08-03 | Sierra Oncology collaborates with Astrazeneca to globally develop and commercialize AZD-5153 and its related compounds for myelofibrosis. | Phase 1/2 | US$216.0M stated total |
| 2018-08-22 | Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences | Phase 3 | US$3.0M upfront; US$195.0M milestones; US$198.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
